Denali Therapeutics Inc.
Anti-TREM2 antibodies and methods of use thereof
Last updated:
Abstract:
In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
Status:
Grant
Type:
Utility
Filling date:
15 Jan 2021
Issue date:
21 Sep 2021